Frank Stegmeier

16.4k citations

34 papers · 4.7k indexed · 2 hit papers · h-index 23

Molecular Biology top 2%
Cell Biology top 0.5%
Oncology top 5%
Cancer Research top 2%
Pulmonary and Respiratory Medicine top 5%

Co-authors: Angelika Amon Stephen J. Elledge William R. Sellers Rosella Visintin Gregory J. Hannon Alice Loo Richard J. Rickles Guang Hu
Topics: CRISPR and Genetic Engineering (10 papers)Microtubule and mitosis dynamics (8 papers)DNA Repair Mechanisms (5 papers)
Cited by: Cell Biology Molecular Biology Cancer Research
Journals: Nature Cell Proceedings of the National Academy of Sciences
Partner nations: United States Switzerland China

In The Last Decade

Frank Stegmeier

33 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Quantitative Proteomics of the Cancer Cell Line Encyclopedia

2020 574 citations Gregory V. Kryukov, Frank Stegmeier et al. Cell profile →
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

2013 425 citations Manav Korpal, Joshua M. Korn et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Frank Stegmeier

Since Specialization

Citations

This map shows the geographic impact of Frank Stegmeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Stegmeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Stegmeier more than expected).

Fields of papers citing papers by Frank Stegmeier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Stegmeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Stegmeier. The network helps show where Frank Stegmeier may publish in the future.

Co-authorship network of co-authors of Frank Stegmeier

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Stegmeier. A scholar is included among the top collaborators of Frank Stegmeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Stegmeier. Frank Stegmeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 1581: KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity with multiple PARP inhibitors in BRCA mutant cancers 2023 ·Cancer Research ·Erica R. Tobin,Pamela Sullivan,(unknown),Hugh Gannon,Anne E. Dodson,Sol Shenker,Frank Stegmeier,Andrew A. Wylie,(unknown)	2
2	Abstract 2771: KSQ-4279 mediated USP1 inhibition induces replication associated DNA gaps that contribute to cell death 2023 ·Cancer Research ·(unknown),Pamela Sullivan,Yuji Mishina,Anne E. Dodson,(unknown),Hugh Gannon,Chris T. Middleton,Sol Shenker,(unknown),Michael R. Schlabach,Frank Stegmeier,Erica R. Tobin,(unknown),Andrew A. Wylie	1
3	Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts 2021 ·Oncogene ·Hendrik J. Kuiken,Sabin Dhakal,Laura M. Selfors,(unknown),Tian Zhang,Maurizio Callari,Ron C.J. Schackmann,G. Kenneth Gray,Jett Crowdis,Hyo-Eun Carrie Bhang,Timour Baslan,Frank Stegmeier,Steven P. Gygi,Carlos Caldas,Joan S. Brugge	5
4	Abstract 1337: Functional genomic characterization of the USP1 inhibitor KSQ-4279 reveals a distinct mechanism of action and resistance profile relative to other DDR targeting drugs 2021 ·Cancer Research ·Sol Shenker,Hugh Gannon,(unknown),Paula Grasberger,Pamela Sullivan,Chris T. Middleton,Anne E. Dodson,Caroline Bullock,Michael H. McGuire,Erica R. Tobin,Kerstin W. Sinkevicius,(unknown),Frank Stegmeier,(unknown),Andrew A. Wylie	7
5	Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer 2015 ·Cancer Research ·Alexandra B. Lantermann,Dongshu Chen,(unknown),Greg Hoffman,Elizabeth Frias,David A. Ruddy,Daniel P. Rakiec,Joshua M. Korn,Gregory McAllister,Frank Stegmeier,Matthew J. Meyer,Sreenath V. Sharma	43
6	A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes 2015 ·Cancer Research ·Qianhe Zhou,Adnan Derti,David A. Ruddy,Daniel P. Rakiec,Iris Kao,(unknown),Veronica Gibaja,Homan Chan,Yi Yang,Junxia Min,Michael R. Schlabach,Frank Stegmeier	57
7	TERT promoter mutations and monoallelic activation of TERT in cancer 2015 ·Oncogenesis ·Franklin W. Huang,Craig M. Bielski,Mikael L. Rinne,William C. Hahn,William R. Sellers,Frank Stegmeier,Levi A. Garraway,Gregory V. Kryukov	72
8	An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)breakdown → 2013 ·Cancer Discovery ·Manav Korpal,Joshua M. Korn,Xueliang Gao,Daniel P. Rakiec,David A. Ruddy,Shivang Doshi,Jing Yuan,Steve G. Kovats,Sunkyu Kim,Vesselina G. Cooke,John E. Monahan,Frank Stegmeier,Thomas M. Roberts,William R. Sellers,Wenlai Zhou,Ping Zhu	425
9	Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas 2011 ·Cancer Research ·Tara L. Naylor,Huaping Tang,Boris A. Ratsch,Andreas Enns,Alice Loo,Liqing Chen,Peter Lenz,Nigel J. Waters,W. Schüler,Bernd Dörken,Yung‐Mae Yao,Markus Warmuth,Georg Lenz,Frank Stegmeier	88
10	The Prp19 complex and the Usp4^Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome 2010 ·Genes & Development ·Eun Joo Song,Shannon L. Werner,(unknown),Frank Stegmeier,Julie L. Aspden,Donald C. Rio,J. Wade Harper,Stephen J. Elledge,Marc W. Kirschner,Michael Rapé	183
11	Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib 2010 ·Clinical Pharmacology & Therapeutics ·Frank Stegmeier,Markus Warmuth,William R. Sellers,Marion Dorsch	148
12	PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers 2009 ·Cancer Research ·Susan Wee,Zainab Jagani,Kay X. Xiang,Alice Loo,Marion Dorsch,Yung‐Mae Yao,William R. Sellers,Christoph Lengauer,Frank Stegmeier	354
13	PTEN-deficient cancers depend on PIK3CB 2008 ·Proceedings of the National Academy of Sciences ·Susan Wee,Dmitri Wiederschain,Sauveur-Michel Maira,Alice Loo,Christine Miller,(unknown),Frank Stegmeier,(unknown),Christoph Lengauer	411
14	Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities 2007 ·Nature ·Frank Stegmeier,Michael Rapé,Viji M. Draviam,Grzegorz Nalepa,Mathew E. Sowa,Xiaolu L. Ang,(unknown),Mamie Z. Li,Gregory J. Hannon,Peter K. Sorger,Marc W. Kirschner,J. Wade Harper,Stephen J. Elledge	301
15	Identification and Classification of Genes That Act Antagonistically to let-60 Ras Signaling in Caenorhabditis elegans Vulval Development 2006 ·Genetics ·Craig J. Ceol,Frank Stegmeier,Melissa M. Harrison,H. Robert Horvitz	36
16	A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells 2005 ·Proceedings of the National Academy of Sciences ·Frank Stegmeier,Guang Hu,Richard J. Rickles,Gregory J. Hannon,Stephen J. Elledge	437
17	The Replication Fork Block Protein Fob1 Functions as a Negative Regulator of the FEAR Network 2004 ·Current Biology ·Frank Stegmeier,Julie Huang,Rami Rahal,(unknown),Danesh Moazed,Angelika Amon	45
18	Cdc14 and Condensin Control the Dissolution of Cohesin-Independent Chromosome Linkages at Repeated DNA 2004 ·Cell ·Damien D’Amours,Frank Stegmeier,Angelika Amon	232
19	The Role of the Polo Kinase Cdc5 in Controlling Cdc14 Localization 2003 ·Molecular Biology of the Cell ·Rosella Visintin,Frank Stegmeier,Angelika Amon	78
20	Separase, Polo Kinase, the Kinetochore Protein Slk19, and Spo12 Function in a Network that Controls Cdc14 Localization during Early Anaphase 2002 ·Cell ·Frank Stegmeier,Rosella Visintin,Angelika Amon	351

About Frank Stegmeier

Frank Stegmeier is a scholar working on Aging, Cell Biology and Molecular Biology, having authored 34 papers that have together received 4.7k indexed citations. Recurring topics across this work include CRISPR and Genetic Engineering (10 papers), Microtubule and mitosis dynamics (8 papers) and DNA Repair Mechanisms (5 papers). The work is most often cited by research in Cell Biology (1.2k citations), Molecular Biology (3.7k citations) and Cancer Research (702 citations). Frank Stegmeier has collaborated with scholars based in United States, Switzerland and China. Frequent co-authors include Angelika Amon, Stephen J. Elledge, William R. Sellers, Rosella Visintin, Gregory J. Hannon, Alice Loo, Richard J. Rickles, Guang Hu, Susan Wee and Christoph Lengauer. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact